All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is a trainee healthcare and pharmaceutical reporter. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
Insilico’s AI-discovered ulcerative colitis drug starts Phase I trial
After the healthy volunteer study, Insilico plans to conduct a Phase Ib trial in patients with ulcerative colitis (UC).
Merck partners with HiberCell for Phase Ib renal carcinoma trial
The Phase Ib trial will evaluate the combination therapy of Welireg and HC-7366 in patients with clear cell renal cell carcinoma.
Alto touts success of EEG biomarker in Phase II MDD trial
ALTO-300-treated patients with an EEG biomarker achieved better clinical response in the major depressive disorder Phase II trial.
Palvella and Ligand partner for Phase III rare lymphatic tumour trial
Palvella will receive $5m as an upfront payment, with Ligand getting 8%-9.8% in tiered royalties on worldwide sales of Qtorin rapamycin.
Lack of women’s data is causing femtech start ups to lose out on VC funding
The lack of data collected on women’s health conditions is forcing femtech companies to conduct lengthy data collection studies which make them ineligible to receive VC funding.
Calliditas starts Phase II trial for rare kidney disease therapy
The placebo-controlled Phase II trial will evaluate setanaxib as a treatment for Alport syndrome, a rare genetic kidney disorder.
Candel downsizes to focus on oncolytic virus-based cancer therapies
Candel has fired 50% of its workforce and directed its resources to advance the development of CAN-2409 and CAN-3110.
FDA rejects Aldeyra’s dry eye drug, asks for more clinical data
Aldeyra has submitted new trial plans to the FDA with anticipated NDA resubmission in H1 2024.
External controls can augment low populations in rare disease trials
The use of external data and computational analysis can bolster clinical trial data in rare and or paediatric trials.
Sanofi and Regeneron’s Dupixent scores second win in Phase III COPD trial
Companies plan to submit the supplemental data on Dupixent to the US Food and Drug Administration (FDA) by the end of 2023.